Compare DexCom, Inc. (DXCM) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs PAGSEG Inc — how do they compare? DexCom, Inc. trades at $77.31 (market cap $28.06B), while PAGSEG Inc trades at $9.21 (market cap $2.57B). The key difference: DexCom, Inc. is far larger — about 10.9× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.29% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PAGS | |
|---|---|---|
Market Cap | $28.06B | $2.57B |
Sector | Health | Technology |
52-Week High | $89.53 | $12.00 |
52-Week Low | $54.84 | $7.75 |
Enterprise Value | $27.03B | $10.21B |
Dividend Yield | — | 11.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
PAGS trades at $9.205, down 0.81% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported 2025 revenue of $20.41B and net income of $2.12B, with strong profitability margins and attractive valuation ratios, including a P/E of 6.52. Recent news highlights PagSeguro's potential benefit from Brazil's rate-cutting cycle and its deep valuation discount.
The outlook for PAGS is positive, driven by robust fundamentals, a favorable analyst consensus, and potential tailwinds from monetary policy. Key risks include macroeconomic pressures in Brazil and competitive threats in the financial services sector. The stock presents a value opportunity with upside potential, contingent on execution and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
